# A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19

> **NCT05815498** · PHASE3 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 13553 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** mRNA-1283.222
- **BIOLOGICAL:** mRNA-1273.222
- **BIOLOGICAL:** mRNA-1283.815
- **BIOLOGICAL:** mRNA-1273.815

## Key facts

- **NCT ID:** NCT05815498
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-28
- **Primary completion:** 2025-04-12
- **Final completion:** 2025-04-12
- **Target enrollment:** 13553 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05815498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05815498, "A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05815498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*